Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Metastasis in non-small cell lung cancer (NSCLC) significantly impacts patient recurrence and survival outcomes. Despite its importance, the factors influencing NSCLC metastasis are not fully understood. This study aimed to explore the association between demographic factors, gene mutation status, and EGFR exon mutation status with NSCLC metastasis, utilizing data from a large cohort of NSCLC patients. This study included a cohort of 1,217 NSCLC patients who received treatment at the First Affiliated Hospital of Chongqing Medical University between December 2019 and November 2023. Comprehensive demographic and clinicopathological data were collected. Mutation status in 9 driver genes and 7 EGFR exon sites were identified. Chi-square or Fisher's exact tests were utilized to examine the associations between these factors and NSCLC metastasis. Logistic regression analysis was conducted to determine the factors influencing metastasis. Among the 1,217 NSCLC patients, 536 (44.0%) experienced lymph node metastasis, and 426 (35.0%) had distant metastasis. A history of smoking emerged as an independent risk factor for lymph node metastasis (OR = 1.79, P = 0.01), with higher T stages correlating with an increased risk of lymph node involvement. Compared to squamous cell carcinoma, adenocarcinoma (OR = 1.95, P < 0.01) and other histological subtypes (OR = 3.62, P < 0.01) were identified as independent risk factors for distant metastasis. RET gene mutation (Mutant vs. Wild-type) was an independent risk factor for distant metastasis (OR = 3.05, P = 0.01). After adjusting for various factors, the Exon 21-L858R mutation (Mutant vs. Wild-type) was independently associated with a lower risk of lymph node metastasis (OR = 0.55, P = 0.002).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370941PMC
http://dx.doi.org/10.1038/s41598-025-15962-1DOI Listing

Publication Analysis

Top Keywords

nsclc metastasis
16
mutation status
12
nsclc patients
12
lymph node
12
metastasis
9
distant metastasis
8
nsclc
8
factors influencing
8
egfr exon
8
1217 nsclc
8

Similar Publications

Purpose: We investigated whether EML4-ALK fusions and mutations in pre-treatment plasma ctDNA predicted time to treatment discontinuation (TTD) in ALK-positive non-small cell lung cancer (ALK+ NSCLC) patients initiating first-line alectinib and evaluated clinical characteristics influencing TTD.

Materials & Methods: 42 patients from five Danish public oncology departments with previously untreated, metastatic ALK+ NSCLC were included in the study. All patients received alectinib, a second-generation ALK inhibitor, as their first-line treatment.

View Article and Find Full Text PDF

Non-small cell lung cancer (NSCLC) is the most common lung cancer type and one of the deadliest neoplasias worldwide. NSCLC is histologically classified into adenocarcinoma, squamous cell carcinoma, and other less frequent subtypes. Both subtypes and other solid tumors are increasingly regarded as abnormal organs, highlighting the critical role of the desmoplastic tumor stroma rich in cancer-associated fibroblasts (CAFs) in driving tumor progression and therapeutic resistance.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: Carissa carandas L. ('Karonda'), a medicinal shrub from the Apocynaceae family, has been traditionally used in Indian ethnomedicine for the treatment of inflammation, infections, and respiratory disorders. Its phytochemically rich extracts have demonstrated diverse pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, and anticancer effects.

View Article and Find Full Text PDF

Importance: It has been stated that especially with the advancements in imaging, systemic therapy, and local radical treatment (LRT) that patients with synchronous oligometastatic disease (sOMD) can potentially benefit from curative-intent treatment. This statement is challenged by the results of the NRG-LU002 randomized phase 2/3 trial, showing no significant progression-free survival and overall survival improvements with the addition of LRT to maintenance systemic therapy in patients with oligometastatic non-small cell lung cancer (NSCLC) who achieved at least stable disease after induction systemic therapy (approximately 90% received an immunotherapy-based regimen). This Review discusses the current challenges and controversies in the treatment of non-oncogene-addicted sOMD.

View Article and Find Full Text PDF